Celcuity (FRA:7VR) Short Interest


FRA:7VR Celcuity Inc FRA:7VR
11 GF Score
Price €87.00
! 2 Warning Signs
View Full Analysis

What is Celcuity Short Interest?

Short Interest can be expressed as a percentage by dividing the number of shares sold short by the total number of outstanding shares.

Due to the license agreement change with our data vendor, Short Interest related data on GuruFocus will no longer be updated. Existing data will remain as-is, while new data will not be available, except for certain Australian and Canadian stocks.

FRA:7VR vs ERAS, TNGX, DNTH: Short Interest Comparison

For the Biotechnology subindustry, Celcuity's Short Interest, along with its competitors' market caps and Short Interest data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Celcuity Short Interest vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Celcuity's Short Interest distribution charts can be found below:

* The bar in red indicates where Celcuity's Short Interest falls into.


FRA:7VR
11GF Score
Celcuity Inc FRA:7VR
Short Interest is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Celcuity Business Description

Other Exchanges CELC:USA
Address 16305 36th Avenue North, Suite 100, Minneapolis, MN, USA, 55446
Celcuity Inc is a clinical-stage biotechnology company developing targeted therapies for multiple solid tumors. Its candidate, gedatolisib, is a kinase inhibitor of the PI3K/AKT/mTOR (PAM) pathway, binding all class I PI3K isoforms and mTORC1/2, offering comprehensive inhibition with a mechanism and pharmacokinetics differentiated from other therapies. The Phase 3 VIKTORIA-1 trial, evaluating gedatolisib with fulvestrant, with or without palbociclib, in HR+/HER2- breast cancer, has completed enrollment and reported results for PIK3CA WT tumors, with cohort 2 (PIK3CA MT) also enrolled. Phase 3 VIKTORIA-2 and Phase 1b/2 CELC-G-201 trials, evaluating combinations in endocrine-resistant HR+/HER2- breast cancer and metastatic castration-resistant prostate cancer, are ongoing.
11GF Score

Get the complete analysis for FRA:7VR

Short Interest is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€87.00
Price